Spanish pharma Almirall has closed a €200 million share capital raise that will be used in part to close pipeline-boosting activities – including bolt-on acquisitions and
With the northern hemisphere summer drawing near, a campaign has been launched to raise awareness of actinic keratosis – a skin condition caused by sun exposure that can l
Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases.
Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable
An alliance between Spanish drugmaker Almirall and digital health company Happify has yielded its first fruit, with the launch of their Claro app designed to reduce anxiety and improve well